Oxygen Biotherapeutics' rollercoaster development of a brain injury treatment has come to a grinding halt, as the biotech has put an end to a mid-stage trial on the drug and is looking to move on.
Novartis is contributing $20 million to build a new, 30,000-square-foot research center at Penn that will concentrate on developing a wave of new immuno-oncology drugs.
Market research firm Allied Market Research forecasts that RNA-based therapies will generate $1.2 billion in revenue by 2020, a compounded annual growth rate of 28.4%, according to a recent report.
The Defense Advanced Research Projects Agency awarded Harvard University engineers up to $2.9 billion to develop a robotic suit to make walking easier for soldiers and potentially civilians with disabilities, the university announced today.
A long, rough patch in Fragile X syndrome drug R&D just got longer and rougher. Roche has notified patient groups that both of its mid-stage studies for RG7090--an mGluR5 therapy--failed to hit the primary and secondary goals, prompting the pharma giant to shut down the program.
As government health agencies and industry players ramp up efforts to bring experimental therapies as quickly as possible to people affected by the Ebola outbreak in West Africa, the Bill and Melinda Gates Foundation said Wednesday that it is putting up $50 million to aid drug development and outbreak response efforts.
Researchers in Singapore have developed a microneedle patch capable of delivering the painkiller lidocaine with just 5 minutes of application, a far cry from the 45 minutes they say is required of those commercially available now.
The U.S. National Institutes of Health devoted $20 million to develop an HIV drug-delivering intravaginal ring. The design of a successful ring is a priority in HIV research, and the sustained release of drugs the ring offers could eventually play a crucial role in HIV prevention in the developing world.
Researchers have designed a novel suppository for HIV antiretroviral delivery using the seaweed extract carrageenan. Almost half of the antiretroviral drug tenofovir diffused out of the delivery mechanism within the first two hours in an in vitro study testing the product in water, vaginal simulant fluid and semen simulant fluid.
Over the last few years, new vector technology has helped inspire a wave of biotech startups involved in developing gene therapies. Now, worried that sticker shock for the $1 million-plus treatments working their way down the pipeline could wind up poisoning the well for everyone, one of the principal academic investigators behind the new technology has been working on a suggestion for a new payment model for these therapies.